The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Express News | Today's stocks have shown unusual movements, with Block Orders selling off electronic and computer stocks | 【Large Amplitude

BreakingsDec 23, 2024 17:06

Express News | Hainan Poly Pharm: Won the bid for the tenth batch of national pharmaceutical centralized procurement.

BreakingsDec 13, 2024 10:07

December 10 A-share investment risk avoidance | Shenzhen SDG Service: Shareholder Silver Kun Company and Longxin Construction plan to collectively shareholding not exceeding 2%.

Hainan Poly Pharm: Currently under investigation by the Securities Regulatory Commission. There is a risk of being subjected to compulsory delisting due to major illegal activities involving stocks.

Gelonghui FinanceDec 9, 2024 22:20

A-share anomaly | Hainan Poly Pharm plunges 14% at the beginning of the day, may face the risk of being (delisted) forcibly.

On December 3, Gelonghui reported that hainan poly pharm (300630.SZ) significantly dropped by 14% at the beginning of the session, now at 10.68 yuan, with the decline narrowed to 8.6%, and the total market value fell below 5 billion yuan. In the news, last night the company disclosed again the 'Announcement on the Progress of the Case Investigation and Risk Warning,' indicating the risk of being subjected to major illegal forced (delisted). Additionally, according to relevant regulations, if the company's stocks are terminated from listing, the convertible bonds issued by the company will also be simultaneously terminated from listing or trading. (Gelonghui)

Gelonghui FinanceDec 3, 2024 09:47

Express News | Hainan Poly Pharm: The company is suspected of violating information disclosure regulations and is currently under investigation by the China Securities Regulatory Commission.

BreakingsNov 25, 2024 21:43